Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Wockhardt's OCF Yield % or its related term are showing as below:
NSE:WOCKPHARMA'
s OCF Yield % Range Over the Past 10 Years
Min: 1.26 Med: 0 Max: 1.26
Current: 1.26
During the past 13 years, the highest OCF Yield % of Wockhardt was 1.26%. The lowest was 1.26%. And the median was %.
NSE:WOCKPHARMA's OCF Yield % is ranked worse than 63.22% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 3.62
vs NSE:WOCKPHARMA: 1.26
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Wockhardt OCF Yield % Related Terms
Wockhardt OCF Yield % Historical Data
* Premium members only.
The historical data trend for Wockhardt's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:WOCKPHARMA vs ZTS, UTHR: OCF Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Wockhardt's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wockhardt OCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Wockhardt's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Wockhardt's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wockhardt (NSE:WOCKPHARMA) has a OCF Yield % of 1.26 as of Jul. 19, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Wockhardt and its competitors. Over the past decade, Wockhardt's OCF Yield % has ranged from 1.26 to 1.26. According to the industry distribution chart, Wockhardt ranks #636 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 63.2%.
Is Wockhardt's OCF Yield % too high?
Wockhardt's current OCF Yield % is 1.26. Over the past 10 years, this metric has ranged from a low of 1.26 to a high of 1.26. The Drug Manufacturers industry median OCF Yield % is 3.62. Wockhardt's value of 1.26 is 65.2% below this industry median. Based on the distribution chart, Wockhardt ranks #636 out of 1006 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Wockhardt has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Wockhardt's OCF Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Wockhardt ranks #636 out of 1006 companies for OCF Yield %. This places Wockhardt in the lower half of its industry. The industry median OCF Yield % is 3.62. Wockhardt's value of 1.26 is 65.2% below this benchmark. Historically, Wockhardt's own OCF Yield % has ranged from 1.26 to 1.26 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Drug Manufacturers company?
The median OCF Yield % among Drug Manufacturers companies is 3.62, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Wockhardt's current OCF Yield % of 1.26 is 65.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Wockhardt and its competitors. For the Drug Manufacturers industry, the median OCF Yield % is 3.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wockhardt's current OCF Yield % is 1.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wockhardt stock overvalued right now?
Based on GuruFocus' analysis, Wockhardt (NSE:WOCKPHARMA) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹1,268.66, compared to a current price of ₹1,900.70 — trading 49.8% above its estimated fair value. The current OCF Yield % is 1.26 and 65.2% below the Drug Manufacturers industry median of 3.62. Wockhardt's overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Wockhardt (NSE:WOCKPHARMA), the current OCF Yield % is 1.26 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wockhardt (NSE:WOCKPHARMA) Overvalued in 2026?
Based on GuruFocus' analysis, Wockhardt stock appears to be overvalued.
The current stock price of ₹1,900.70 is trading 49.8% above its estimated GF Value™ of ₹1,268.66.
GuruFocus considers Wockhardt to be Significantly Overvalued.
Key valuation signals for NSE:WOCKPHARMA:
OCF Yield %: 1.26
GF Value™: ₹1,268.66 vs. price of ₹1,900.70 (49.8% above fair value)
Industry Position: 65.2% below the Drug Manufacturers median (#636 of 1006)
No single metric tells the full story. See the NSE:WOCKPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wockhardt Ltd is a drug manufacturing company focusing on pharmaceutical and biotechnology products. The group is involved in new drug discovery, contract manufacturing, API, vaccines, and branded pharmaceuticals business. In addition, it operates a chain of super-specialty hospitals. Its novel antibiotic platform has various assets, such as Zaynich (WCK 5222); Miqnaf (Nafithromycin), a macrolide-class respiratory antibiotic; Ertapenem-Zidebactam (WCK 6777); Foviscu (WCK 2482), an antibiotic for Gram-negative infections; and Odrate (WCK 6777), among others. The group is mainly engaged in the pharmaceutical business, which is considered its only reportable business segment. Geographically, it generates maximum revenue from Europe, followed by India, the USA, and the Rest of the world.
59GF Score
Get the complete analysis for NSE:WOCKPHARMA
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:WOCKPHARMA has been successfully added to your 
